OPKO Health (NASDAQ:OPK – Get Free Report) and PROCEPT BioRobotics (NASDAQ:PRCT – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation and dividends.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for OPKO Health and PROCEPT BioRobotics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| OPKO Health | 1 | 3 | 2 | 1 | 2.43 |
| PROCEPT BioRobotics | 2 | 4 | 8 | 0 | 2.43 |
OPKO Health currently has a consensus price target of $2.03, suggesting a potential upside of 78.36%. PROCEPT BioRobotics has a consensus price target of $40.82, suggesting a potential upside of 62.49%. Given OPKO Health’s higher probable upside, research analysts plainly believe OPKO Health is more favorable than PROCEPT BioRobotics.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| OPKO Health | $606.90 million | 1.43 | -$225.68 million | ($0.30) | -3.80 |
| PROCEPT BioRobotics | $308.05 million | 4.60 | -$95.57 million | ($1.71) | -14.69 |
PROCEPT BioRobotics has lower revenue, but higher earnings than OPKO Health. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than OPKO Health, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
OPKO Health has a beta of 1.49, meaning that its stock price is 49% more volatile than the S&P 500. Comparatively, PROCEPT BioRobotics has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500.
Insider and Institutional Ownership
64.6% of OPKO Health shares are held by institutional investors. Comparatively, 89.5% of PROCEPT BioRobotics shares are held by institutional investors. 49.7% of OPKO Health shares are held by company insiders. Comparatively, 6.6% of PROCEPT BioRobotics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Profitability
This table compares OPKO Health and PROCEPT BioRobotics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| OPKO Health | -37.19% | -17.42% | -11.24% |
| PROCEPT BioRobotics | -31.02% | -25.13% | -18.63% |
Summary
OPKO Health beats PROCEPT BioRobotics on 9 of the 14 factors compared between the two stocks.
About OPKO Health
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.
About PROCEPT BioRobotics
PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.
Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.
